256:
233:
628:
29:
430:
with two amide groups; it was first published in 2000. It was submitted for regulatory approval in Japan in 2003; the application was withdrawn in 2009, and it was resubmitted with additional data in 2011 and approved for marketing in Japan in 2012.
515:"Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models"
730:
705:
59:
676:
725:
328:
342:
695:
669:
662:
362:
83:
370:
InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)
720:
172:
212:
439:
market it in Japan. Approval was obtained in China in 2011 by
Simcere, independently of the Japanese originators.
442:
During discovery and development it was called T-614 and it is marketed under the names
Careram and Kolbet.
514:
470:
Tanaka K, Yamaguchi T, Hara M (May 2015). "Iguratimod for the treatment of rheumatoid arthritis in Japan".
251:
420:
201:
700:
393:
715:
642:
228:
107:
710:
495:
554:
Bronson J, Dhar M, Ewing W, Lonberg N (2012). "Chapter Thirty-One – To Market, To Market—2011".
536:
487:
401:
389:
41:
646:
563:
526:
479:
268:
161:
116:
181:
639:
436:
432:
255:
232:
635:
567:
689:
244:
499:
603:
581:
397:
141:
483:
627:
304:
152:
540:
513:
Inaba T, Tanaka K, Takeno R, Nagaki H, Yoshida C, Takano S (January 2000).
491:
20:
427:
426:
It is a derivative of 7-methanesulfonylamino-6-phenoxychromones and is a
413:
405:
531:
127:
28:
192:
409:
327:
318:
217:
423:, nausea, vomiting, stomach pain; rashes, and itchiness.
650:
316:
303:
267:
262:
243:
211:
191:
171:
151:
126:
106:
74:
58:
50:
40:
35:
408:activation and subsequently selectively inhibits
350:O=S(=O)(Nc3c(Oc1ccccc1)cc2c(O/C=C(\C2=O)NC=O)c3)C
140:
115:
731:Antineoplastic and immunomodulating drug stubs
392:small molecule drug used for the treatment of
670:
8:
706:Anti-inflammatory and antirheumatic products
465:
463:
461:
459:
457:
455:
19:
16:Chemical compound with medical applications
677:
663:
254:
231:
160:
27:
530:
180:
726:Drugs with unknown mechanisms of action
451:
367:
347:
227:
88:
519:Chemical & Pharmaceutical Bulletin
245:
18:
556:Annual Reports in Medicinal Chemistry
200:
7:
624:
622:
472:Expert Review of Clinical Immunology
400:in Japan and China. As of 2015 the
131:
649:. You can help Knowledge (XXG) by
568:10.1016/B978-0-12-396492-2.00031-X
14:
626:
285:
279:
98:-chromen-7-yl)methanesulfonamide
404:was not known, but it prevents
375:Key:ANMATWQYLIFGOK-UHFFFAOYSA-N
94:-(3-Formamido-4-oxo-6-phenoxy-4
696:Drugs not assigned an ATC code
604:"Iguratimod - Toyama Chemical"
297:
291:
273:
1:
484:10.1586/1744666X.2015.1027151
747:
621:
263:Chemical and physical data
412:and several inflammatory
358:
338:
79:
26:
419:Adverse effects include
582:"Iguratimod - Simcere"
421:elevated transaminases
721:Small-molecule drugs
394:rheumatoid arthritis
23:
532:10.1248/cpb.48.131
658:
657:
402:biological target
390:anti-inflammatory
383:
382:
329:Interactive image
213:CompTox Dashboard
738:
679:
672:
665:
640:immunomodulatory
630:
623:
616:
615:
613:
611:
600:
594:
593:
591:
589:
578:
572:
571:
551:
545:
544:
534:
510:
504:
503:
467:
396:, together with
331:
311:
299:
293:
287:
281:
275:
258:
247:
236:
235:
221:
219:
204:
184:
164:
144:
134:
133:
119:
31:
24:
22:
746:
745:
741:
740:
739:
737:
736:
735:
686:
685:
684:
683:
620:
619:
609:
607:
602:
601:
597:
587:
585:
580:
579:
575:
553:
552:
548:
512:
511:
507:
469:
468:
453:
448:
437:Toyama Chemical
379:
376:
371:
366:
365:
354:
351:
346:
345:
334:
309:
296:
290:
284:
278:
239:
215:
207:
187:
167:
147:
130:
122:
102:
99:
87:
86:
70:
46:Careram; Kolbet
17:
12:
11:
5:
744:
742:
734:
733:
728:
723:
718:
713:
708:
703:
698:
688:
687:
682:
681:
674:
667:
659:
656:
655:
636:antineoplastic
631:
618:
617:
595:
573:
546:
505:
450:
449:
447:
444:
381:
380:
378:
377:
374:
372:
369:
361:
360:
359:
356:
355:
353:
352:
349:
341:
340:
339:
336:
335:
333:
332:
324:
322:
314:
313:
307:
301:
300:
294:
288:
282:
276:
271:
265:
264:
260:
259:
249:
241:
240:
238:
237:
224:
222:
209:
208:
206:
205:
197:
195:
189:
188:
186:
185:
177:
175:
169:
168:
166:
165:
157:
155:
149:
148:
146:
145:
137:
135:
124:
123:
121:
120:
112:
110:
104:
103:
101:
100:
90:
82:
81:
80:
77:
76:
72:
71:
69:
68:
64:
62:
56:
55:
52:
48:
47:
44:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
743:
732:
729:
727:
724:
722:
719:
717:
714:
712:
709:
707:
704:
702:
699:
697:
694:
693:
691:
680:
675:
673:
668:
666:
661:
660:
654:
652:
648:
645:article is a
644:
641:
637:
632:
629:
625:
606:. AdisInsight
605:
599:
596:
584:. AdisInsight
583:
577:
574:
569:
565:
561:
557:
550:
547:
542:
538:
533:
528:
524:
520:
516:
509:
506:
501:
497:
493:
489:
485:
481:
478:(5): 565–73.
477:
473:
466:
464:
462:
460:
458:
456:
452:
445:
443:
440:
438:
434:
429:
424:
422:
417:
415:
411:
407:
403:
399:
395:
391:
387:
373:
368:
364:
357:
348:
344:
337:
330:
326:
325:
323:
320:
315:
308:
306:
302:
272:
270:
266:
261:
257:
253:
250:
248:
246:ECHA InfoCard
242:
234:
230:
229:DTXSID0048971
226:
225:
223:
214:
210:
203:
202:ChEMBL2107455
199:
198:
196:
194:
190:
183:
179:
178:
176:
174:
170:
163:
159:
158:
156:
154:
150:
143:
139:
138:
136:
129:
125:
118:
114:
113:
111:
109:
105:
97:
93:
89:
85:
78:
73:
66:
65:
63:
61:
57:
53:
49:
45:
43:
39:
36:Clinical data
34:
30:
25:
701:Sulfonamides
651:expanding it
633:
608:. Retrieved
598:
586:. Retrieved
576:
559:
555:
549:
525:(1): 131–9.
522:
518:
508:
475:
471:
441:
425:
418:
398:methotrexate
385:
384:
95:
91:
562:: 499–569.
312: g·mol
252:100.236.037
117:123663-49-0
75:Identifiers
51:Other names
42:Trade names
716:Formamides
690:Categories
446:References
386:Iguratimod
317:3D model (
305:Molar mass
182:4IHY34Y2NV
153:ChemSpider
108:CAS Number
84:IUPAC name
21:Iguratimod
711:Chromones
414:cytokines
541:10705489
500:25134255
492:25797025
428:chromone
60:ATC code
269:Formula
128:PubChem
610:27 May
588:27 May
539:
498:
490:
388:is an
343:SMILES
310:374.37
193:ChEMBL
162:110694
142:124246
634:This
496:S2CID
433:Eisai
410:COX-2
406:NF-κB
363:InChI
319:JSmol
54:T-614
647:stub
643:drug
612:2018
590:2018
537:PMID
488:PMID
435:and
173:UNII
67:None
638:or
564:doi
527:doi
480:doi
218:EPA
132:CID
692::
560:47
558:.
535:.
523:48
521:.
517:.
494:.
486:.
476:11
474:.
454:^
416:.
283:14
277:17
678:e
671:t
664:v
653:.
614:.
592:.
570:.
566::
543:.
529::
502:.
482::
321:)
298:S
295:6
292:O
289:2
286:N
280:H
274:C
220:)
216:(
96:H
92:N
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
